The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
INVOKE: A phase 1 study of OKN4395, a first-in-class EP2/EP4/DP1 triple prostanoid receptor antagonist, in patients with advanced solid tumors.
 
Neal Chawla
No Relationships to Disclose
 
Luke Kuttschreuter
Employment - Owkin; Pfizer
Stock and Other Ownership Interests - Owkin; Pfizer
Expert Testimony - Pfizer
Travel, Accommodations, Expenses - Pfizer
 
Kamlesh Sankhala
Consulting or Advisory Role - Daichi; SpringWorks Therapeutics
Speakers' Bureau - AADi; SpringWorks Therapeutics
Research Funding - Running clinical trials from various sponsors (Inst)
Travel, Accommodations, Expenses - Daiichi (Inst)
 
Sarah Benafif
No Relationships to Disclose
 
Louise Carter
Consulting or Advisory Role - Athenex; Bicycle Therapeutics; Boehringer Ingelheim
Research Funding - ADC Therapeutics (Inst); Athenex (Inst); Bicycle Therapeutics (Inst); Boehringer Ingelheim (Inst); CellCentric (Inst); Corbus Pharmaceuticals (Inst); CytomX Therapeutics (Inst); Kronos Bio (Inst); Lilly (Inst); Loxo/Lilly (Inst); Lupin Pharmaceuticals (Inst); Merck Serono (Inst); Nurix (Inst); Owkin (Inst); Repare Therapeutics (Inst); Sierra Oncology (Inst); Step Pharma (Inst); Takeda (Inst)
 
Nicholas Coupe
Honoraria - Bristol Myers Squibb Foundation; Pierre Fabre
Travel, Accommodations, Expenses - Pierre Fabre
 
T.R. Jeffry Evans
Honoraria - Ascelia (Inst); AstraZeneca (Inst); Bicycle Therapeutics (Inst); Bristol Myers Squibb (Inst); CV6 Therapeutics (Inst); Eisai (Inst); Medivir (Inst); Merck Sharp & Dohme (Inst); Nucana (Inst); Roche/Genentech (Inst); Seagen (Inst)
Consulting or Advisory Role - Karus Therapeutics (Inst)
Speakers' Bureau - AstraZeneca (Inst); Bristol Myers Squibb (Inst); Eisai (Inst); Ewopharma (Inst); Medivir (Inst); Merck Sharp & Dohme (Inst); Nucana (Inst); Roche/Genentech (Inst); United Medical (Inst)
Research Funding - Adaptimmune (Inst); Amgen (Inst); Astellas Pharma (Inst); AstraZeneca (Inst); Athenex (Inst); Avacta Life Sciences (Inst); Basilea (Inst); Bayer (Inst); Beigene (Inst); Berg Pharma (Inst); Bicycle Therapeutics (Inst); BiolineRx (Inst); BioNTech (Inst); Boehringer Ingelheim (Inst); Bristol Myers Squibb (Inst); Celgene (Inst); Clovis Oncology (Inst); Codiak BioSciences (Inst); CV6 Therapeutics (Inst); CytomX Therapeutics (Inst); Eisai (Inst); Exelixis (Inst); Exscientia (Inst); GlaxoSmithKline (Inst); Halozyme (Inst); Immunocore (Inst); iOnctura (Inst); Iovance Biotherapeutics (Inst); Janssen (Inst); Johnson & Johnson (Inst); Lilly (Inst); Medivir (Inst); Merck Serono (Inst); Merck Sharp & Dohme (Inst); MiNA Therapeutics (Inst); Moderna Therapeutics (Inst); Modulate Pharma (Inst); Novartis (Inst); Nucana (Inst); Nurix (Inst); Pfizer (Inst); Plexxikon (Inst); Roche/Genentech (Inst); Sanofi/Aventis (Inst); Sapience Therapeutics (Inst); Seagen (Inst); Sierra Pharma (Inst); Sotio (Inst); Starpharma (Inst); T3 Pharmaceuticals (Inst); UCB (Inst); Verastem (Inst); Vertex (Inst)
Expert Testimony - iOnctura (Inst); Medivir (Inst)
Travel, Accommodations, Expenses - Bristol Myers Squibb; Eisai; Merck Sharp & Dohme; Nucana; Pierre Fabre; Roche
Other Relationship - Genmab (Inst)
 
Timothy Humphries
No Relationships to Disclose
 
Steven Kao
Honoraria - AstraZeneca/UK; BeiGene; Bristol-Myers Squibb; Daiichi Sankyo; MSD; Pfizer; Roche; Takeda
Consulting or Advisory Role - Amgen; AstraZeneca/UK; BeiGene; Boehringer Ingelheim; Bristol-Myers Squibb; Daiichi Sankyo; MSD; Pfizer; Roche; Takeda
Research Funding - AstraZeneca/UK (Inst)
Other Relationship - Pfizer
 
Harriet Walter
Consulting or Advisory Role - AstraZeneca/UK; BeiGene
Research Funding - BeiGene (Inst)
 
Andy Karabajakian
No Relationships to Disclose
 
Alexandre Grimaldi
Employment - Owkin
 
Caroline Hoffmann
Employment - Owkin
Consulting or Advisory Role - Nanobiotix
 
Gill Low
No Relationships to Disclose
 
Andrew Pierce
Employment - Crescendo Biologics; Owkin
 
Stephane Champiat
Honoraria - Amgen; Astellas Pharma; AstraZeneca; Bristol-Myers Squibb; Eisai Europe; Fresenius Kabi; Genmab; Janssen; Merck KGaA; Merck Serono; MSD; Novartis; Roche; SERVIER; Takeda
Consulting or Advisory Role - Alderaan Biotechnology; Amgen; AstraZeneca; Avacta Life Sciences; BeiGene; BioNTech SE; Celanese; Domain Therapeutics; Ellipses Pharma; Genmab; Immunicom; Mariana Oncology; Nanobiotix; NextCure; Oncovita; Pierre Fabre; Seagen; Takeda; Tatum Bioscience; Tollys; UltraHuman8
Research Funding - Abbvie; Abbvie (Inst); Adaptimmune (Inst); Adlai Nortye (Inst); Aduro Biotech (Inst); Agios (Inst); Amgen; Amgen (Inst); arGEN-X BVBA (Inst); Arno Therapeutics (Inst); Astex Pharmaceuticals (Inst); AstraZeneca (Inst); AstraZeneca (Inst); AVEO (Inst); Basilea Pharmaceutical (Inst); Bayer (Inst); BB Biotech Ventures (Inst); BBB Technologies (Inst); BeiGene (Inst); Bicycle Therapeutics (Inst); BioAlliance Pharma (Inst); BioNTech (Inst); Blueprint Medicines (Inst); Boehringer Ingelheim; Boehringer Ingelheim (Inst); Boehringer Ingelheim (Inst); Bolt Biotherapeutics; Boston Pharmaceuticals (Inst); Bristol-Myers Squibb (Inst); Bristol-Myers Squibb (Inst); CASI Pharmaceuticals (Inst); Celgene (Inst); CellCentric (Inst); Centessa Pharmaceuticals; Cephalon (Inst); Chugai Pharma (Inst); Clovis Oncology (Inst); Cullinan Oncology (Inst); CureVac (Inst); Cytovation; Daiichi Sankyo (Inst); Debiopharm Group (Inst); Eisai (Inst); Eisai/H3 Biomedicine; Exelixis (Inst); Faron Pharmaceuticals (Inst); FORMA Therapeutics (Inst); GamaMabs Pharma (Inst); Genentech (Inst); Gilead Sciences (Inst); GlaxoSmithKline; GlaxoSmithKline (Inst); GlaxoSmithKline (Inst); Glenmark (Inst); H3 Biomedicine (Inst); ImCheck therapeutics; Immunocore; Incyte (Inst); Innate Pharma (Inst); ITeos Therapeutics (Inst); Janssen-Cilag (Inst); Janssen-Cilag (Inst); Kura Oncology (Inst); Kyowa Hakko Kirin (Inst); Lilly (Inst); Loxo (Inst); Lytix Biopharma (Inst); MedImmune (Inst); Menarini (Inst); Merck (Inst); Merck KGaA (Inst); Merck Sharp & Dohme (Inst); Merrimack (Inst); Merus (Inst); Millennium (Inst); Molecular Partners; Molecular Partners (Inst); MSD; Nanobiotix (Inst); Nektar (Inst); Nerviano Medical Sciences (Inst); Novartis (Inst); Novartis (Inst); Octimet (Inst); Oncoethix (Inst); OncoMed (Inst); Oncopeptides (Inst); Onyx (Inst); Orion (Inst); Oryzon Genomics (Inst); OSE Immunotherapeutics; Ose Pharma (Inst); Pfizer (Inst); Pfizer (Inst); PharmaMar (Inst); Philogen (Inst); Pierre Fabre; Pierre Fabre (Inst); Pierre Fabre (Inst); Plexxikon (Inst); Relay Therapeutics (Inst); Replimune; RigonTEC (Inst); Roche (Inst); Roche (Inst); Roche/Genentech; Sanofi; Sanofi (Inst); Sanofi/Aventis (Inst); Seagen; Seagen (Inst); SERVIER (Inst); Sierra Oncology (Inst); Sotio; Sotio (Inst); Syros Pharmaceuticals (Inst); Taiho Pharmaceutical (Inst); Tesaro (Inst); Tioma Therapeutics (Inst); Transgene; Transgene (Inst); Turning Point Therapeutics (Inst); Veracyte (Inst); Wyeth (Inst); Xencor (Inst); Y's Therapeutics (Inst)
Patents, Royalties, Other Intellectual Property - T-cell immunogens derived from anti-viral proteins and methods of using same WO2010039223A2
Travel, Accommodations, Expenses - Amgen; AstraZeneca; Boehringer Ingelheim; Bristol-Myers Squibb; Merck; MSD; OSE Immunotherapeutics; Roche; Sotio
Other Relationship - AstraZeneca (Inst); Bayer (Inst); Boehringer Ingelheim (Inst); Boehringer Ingelheim (Inst); Bristol-Myers Squibb (Inst); GlaxoSmithKline (Inst); Johnson & Johnson (Inst); Lilly (Inst); MedImmune (Inst); Merck (Inst); NH TherAguix (Inst); Pfizer (Inst); Roche (Inst); Roche (Inst)